Clinical trials: Raynaud's Disease
Raynaud's Phenomenon, Skin Necrosis
Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands
The purpose of this study is to evaluate the prognostic influence of light rheography measurement at the fingertips from subjects with secundary Raynaud syndrome.
- Trial name
- Anti-Vasospasm (NCT01378845)
- Testing
- Tracleer, Prostavasin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Christoph Hehrlein
Microstomia, Scleroderma
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
The principal objective is to measure the degree to which oral microstomia caused by sclerosing skin disease improves after treating patients with local hyaluronidase injections.
- Conditions
- Microstomia, Scleroderma, CREST Syndrome, Scleromyxedema
- Trial name
- NCT04656704
- Testing
- hyaluronidase injected intradermally
- Sponsor
- Brigham and Women's Hospital
Systemic Sclerosis (SSc)
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial.
- Trial name
- ASScERT-QoL (NCT06675344)
- Testing
- Apollo Neuro Device
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- Robyn T. Domsic, MD, MPH
Raynaud Disease
Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms
The purpose of this study is to determine if Vascana, a novel topical formulation of nitroglycerin, is effective in the treatment and prevention of the symptoms associated with Raynaud's Phenomenon.
- Trial name
- NCT00934427
- Testing
- 0.9% nitroglycerin in TAM cream, vehicle cream
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- MediQuest Therapeutics
Systemic Sclerosis, Fatigue
Apollo Device for Fatigue in Systemic Sclerosis
The purpose of this study is to learn about the effect of Apollo (a vibrating wearable about the side of an Apple Watch) on fatigue, Raynaud symptoms, depression, quality of life, and disease symptoms in patients with systemic…
- Conditions
- Systemic Sclerosis, Fatigue, Raynaud Phenomenon
- Trial name
- NCT04854850
- Testing
- Apollo
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Robyn T. Domsic, MD, MPH
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
- Trial name
- NCT00378521
- Testing
- MQX-503
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
Raynaud's Phenomenon Isolated Primary, Raynaud's Phenomenon (Secondary)
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.
The investigators seek to perform a comparative transcriptome analysis of TRP channels residing in the skin between primary and scleroderma secondary Raynaud's phenomenon and healthy subjects.
- Conditions
- Raynaud's Phenomenon Isolated Primary, Raynaud's Phenomenon (Secondary), Healthy
- Trial name
- TRP (NCT03211325)
- Testing
- Biopsy
- Where
- France
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Raynaud Disease, Scleroderma, Systemic
Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.
The aim of the study is to determine if postocclusive hyperemia of palmar and dorsal face of the hand with Laser speckle contrast imaging discriminate between patients with systemic sclerosis, subjects with primary Raynaud's…
- Trial name
- SPECIES (NCT01743612)
- Testing
- laser speckle contrast imaging, Cooling
- Where
- 2 sites in France
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Systemic Sclerosis, Raynaud Phenomenon
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
The goal of this observational pilot data acquisition study is to establish if target users can obtain diagnostic quality images in the clinic, from participants with Systemic Sclerosis (SSc), and SSc spectrum conditions.
- Trial name
- NCT06291142
- Testing
- Observation - Nailfold capillaroscopy
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Scleroderma, Systemic, Scleroderma, Diffuse
Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Early phases of systemic sclerosis is characterized by inflammatory and microvasculature alterations. Sildenafil citrate has been shown to have vasodilatory effects and to enhance vasculogenesis.
- Conditions
- Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma, Limited, Raynaud Phenomenon
- Trial name
- NCT01347008
- Testing
- Sildenafil citrate
- Where
- Brazil
- Volunteers
- 41 people
- Sponsor
- Federal University of São Paulo
Cold Hypersensitivity, Vascular System Injuries
Treatment of Frostbite Sequelae With Botulinum Toxin A
Background Digital vasospasm as part of frostbite sequelae is comparable to the vasospastic disorders found in Raynaud's phenomenon which has been successfully treated with Botulinum toxin type A injections in the palm of the…
- Conditions
- Cold Hypersensitivity, Vascular System Injuries, Vibration; Disorder, Sensory Disorders
- Trial name
- NCT06460194
- Testing
- Botuinum toxin
- Where
- Norway
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital of North Norway
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
Systemic sclerosis (SSc) is a rare autoimmune disease in which many patients experience Raynaud's phenomenon (RP) - painful episodes where commonly fingers or toes change color and become painful, numb, or tingly, usually…
- Trial name
- RE-WARM (NCT07748000)
- Testing
- LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm
- Volunteers
- 75 people
- Sponsor
- Liquidia Technologies, Inc.
Systemic Sclerosis (SSc), Raynaud Disease Secondary to Scleroderma
Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary Raynaud's Phenomenon
Raynaud's Phenomenon (RP), a vasospastic disorder causing digital ischemia and potential tissue necrosis, is effectively treated with Botulinum Toxin Type A (BTX-A) in refractory cases.
- Trial name
- Botox SSc-RP (NCT07759557)
- Testing
- Botulinum toxin A via microneedle, Control (Normal saline)
- Volunteers
- 72 people
- Sponsor
- Khon Kaen University
Raynaud's Phenomenon
Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon
Raynaud's phenomenon (RP) is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. During an attack of RP which commonly affects the hands and feet these arteries contract briefly which limits…
- Trial name
- REINO (NCT01315899)
- Testing
- ORM-12471 30mg, ORM-12471
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Orion Corporation, Orion Pharma
Raynaud's Phenomenon
MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison
The purpose of this clinical study is to compare the pharmacokinetic profiles of a topical cream formulation of 0.9% nitroglycerin, MQX 503, and Nitroglycerin Ointment 2%, USP.
- Trial name
- NCT00841594
- Testing
- nitroglycerin 0.9 % (MXQ-503), Nitroglycerin ointment 2%, USP
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
Raynaud Disease, Systemic Sclerosis
Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study
This study evaluates the efficacy and safety of routine medical treatments of digital ulcers in patients with systemic sclerosis in a prospective cohort study.
- Conditions
- Raynaud Disease, Systemic Sclerosis, Digital Ulcer
- Trial name
- NCT02642146
- Testing
- Calcium Channel Blockers, Phosphodiesterase Inhibitors, Endothelin receptor blocker
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Seoul National University Hospital
Buerger Disease, Raynaud Syndrome
Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease
The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease.
- Trial name
- BETOX (NCT05698979)
- Testing
- BOTOX INJECTION
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Toulouse
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with…
- Trial name
- NCT04040322
- Testing
- Iloprost Injection, for intravenous use
- Where
- 30 sites in United States
- Volunteers
- 198 people
- Sponsor
- Civi Biopharma, Inc.
Systemic Sclerosis
Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction
Purpose of the study is to evaluate the effectiveness and safety of a new investigational dur, IC351. Study is designed to gather information regarding the possible usefulness of IC351 as a treatment of several blood vessel…
- Trial name
- NCT00707187
- Testing
- Cialis
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Systemic Sclerosis, Raynaud Phenomenon
Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
In this feasibility study, we aim to explore therapeutic Rheopheresis (RheoP) as a novel treatment option for SSc-associated Raynaud's phenomenon and/or digital ulcers and compare it to the standard of care treatment (intravenous…
- Conditions
- Systemic Sclerosis, Raynaud Phenomenon, Digital Ulcer, Scleroderma
- Trial name
- RHEACT (NCT05204784)
- Testing
- Rheopheresis treatment, Intravenous Infusion
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Peter Korsten